Clinical Trial Update: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria [Phase 2]

View source ↗

Summary

Phase 2 trial results assess the efficacy and safety of lorundrostat added to SGLT2 inhibitors in patients with hypertension and chronic kidney disease with alb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hypertension

Drugs mentioned

• Lorundrostat (lorundrostat)
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: Mineralys Therapeutics Inc. | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED